Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from ValiRx plc ( (GB:VAL) ) is now available.
ValiRx has announced that Ambrose Healthcare has exercised its option to license the VAL401 asset from ValiSeek Limited for £16 million plus royalties. This agreement marks a significant step for ValiRx, as it allows for the further development and commercialization of VAL401, a repurposed Risperidone asset with anticancer effects. The partnership with Ambrose, a specialist pharmaceutical company, aims to advance treatments for rare diseases, including pancreatic cancer, and underscores the strategic focus on innovative therapies. The collaboration is expected to enhance ValiRx’s industry positioning and provide potential therapeutic benefits across multiple cancer indications.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, aiming to accelerate the translation of innovative science into impactful medicines. The company provides a framework for rapid translation of scientific discoveries into clinical development and connects diverse disciplines to streamline and reduce the cost of drug development. ValiRx’s lead candidates are outlicensed or partnered for further development and commercialization.
Average Trading Volume: 1,892,804
Technical Sentiment Signal: Sell
Current Market Cap: £1.78M
See more insights into VAL stock on TipRanks’ Stock Analysis page.